CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells

Biochemical Pharmacology

Volumn 90, Issue 3, 2014, Pages 212-225

  Wang, Yu ^a   Miao, Hanchi ^a   Li, Wei ^a   Yao, Jing ^a   Sun, Yang ^a   Li, Zhiyu ^a   Zhao, Li ^a   Guo, Qinglong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CXCL12 CXCR4 axis; K562 ADM; Oroxylin A; PI3K Akt NF B pathway; Reversal effect

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DIMER; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OROXYLIN A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL NUCLEUS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; K562 CELL LINE; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADRIAMYCIN (PUBCHEM CID: 31703); AGAROSE (PUBCHEM CID: 11966311); CXCL12/CXCR4 AXIS; DAPI (PUBCHEM CID: 2954); DMSO (PUBCHEM CID: 679); K562/ADM; MTT FORMAZAN (PUBCHEM CID: 16218671); OROXYLIN A; OROXYLIN A (PUBCHEM CID: CID 5320315); PI3K/AKT/NF-ΚB PATHWAY; REVERSAL EFFECT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CHEMOKINE CXCL12; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLAVONOIDS; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MICE; MICE, NUDE; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; RANDOM ALLOCATION; RECEPTORS, CXCR4; RNA INTERFERENCE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903879011     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.05.007     Document Type: Article

References (54)

1. A. Garuti, A. Cagnetta, C. Marani, M. Miglino, M. Cea, and I. Rocco et al. Evaluating treatment response of chronic myeloid leukemia: emerging science and technology Curr Cancer Drug Targets 13 2013 779 790
2. A. Cai, D.B. Keskin, D.S. DeLuca, A. Alonso, W. Zhang, and G.L. Zhang et al. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients Clin Cancer Res 18 2012 5761 5772
3. M. Savona, and M. Talpaz Getting to the stem of chronic myeloid leukaemia Nat Rev Cancer 8 2008 341 350 (Pubitemid 351589698)
4. N. Ishibe CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not Blood 100 2002 1100 1101 (Pubitemid 34832653)
5. B.A. Teicher, and S.P. Fricker CXCL12 (SDF-1)/CXCR4 pathway in cancer Clin Cancer Res 16 2010 2927 2931
6. F. Vianello, F. Villanova, V. Tisato, S. Lymperi, K.K. Ho, and A.R. Gomes et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis Haematologica 95 2010 1081 1089
7. Y. Yang, S. Mallampati, B. Sun, J. Zhang, S.B. Kim, and J.S. Lee et al. Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target Cancer Lett 333 2013 9 17
8. J.F. Fecteau, D. Messmer, S. Zhang, B. Cui, L. Chen, and T.J. Kipps Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia Blood 121 2013 971 974
9. J.A. Burger, and A. Peled CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers Leukemia 23 2008 43 52
10. Z. Zeng, Y. Xi Shi, I.J. Samudio, R.Y. Wang, X. Ling, and O. Frolova et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML Blood 113 2008 6215 6224
11. D. Wong, and W. Korz Translating an antagonist of chemokine receptor CXCR4: from bench to bedside Clin Cancer Res 14 2008 7975 7980
12. K. He, T. Xu, Y. Xu, A. Ring, M. Kahn, and A. Goldkorn Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/beta-catenin/CBP pathway Int J Cancer 134 2014 43 54
13. Y. Tabe [Molecular diagnosis of and molecular targeting therapy for leukemia] Rinsho Byori 57 2009 137 145
14. B. Stamatopoulos, N. Meuleman, C. De Bruyn, K. Pieters, P. Mineur, and C. Le Roy et al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments Haematologica 97 2011 608 615
15. M. Niedermeier, B.T. Hennessy, Z.A. Knight, M. Henneberg, J. Hu, and A.V. Kurtova et al. Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach Blood 113 2009 5549 5557
16. H.B. Li, and F. Chen Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography J Chromatogr A 1074 2005 107 110 (Pubitemid 40615049)
17. L. Zhao, Z. Chen, J. Wang, L. Yang, Q. Zhao, and J. Wang et al. Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice Cancer Chemother Pharmacol 65 2009 481 489
18. Y. Gao, N. Lu, Y. Ling, Y. Chen, L. Wang, and Q. Zhao et al. Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation J Cancer Res Clin Oncol 136 2009 667 675
19. L. Zhu, L. Zhao, H. Wang, Y. Wang, D. Pan, and J. Yao et al. Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest Toxicol Lett 219 2013 107 115
20. B. Zhu, L. Zhao, L. Zhu, H. Wang, Y. Sha, and J. Yao et al. Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinβ1 and its related pathway Toxicol Appl Pharmacol 259 2012 387 394
21. H-Y. Yang, L. Zhao, Z. Yang, Q. Zhao, L. Qiang, and J. Ha et al. Oroxylin a reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-κB signaling pathway Mol Carcinog 51 2012 185 195
22. A.B. Das, P. Loying, and B. Bose Human recombinant Cripto-1 increases doubling time and reduces proliferation of HeLa cells independent of pro-proliferation pathways Cancer Lett 318 2012 189 198
23. Y. Zhong, F. Zhang, Z. Sun, W. Zhou, Z.-Y. Li, and Q.-D. You et al. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response Mol Carcinog 52 2013 823 834
24. X. Li, B. Sun, C-J. Zhu, H-Q. Yuan, Y-Q. Shi, and J. Gao et al. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells Toxicol In Vitro 23 2009 29 36
25. L. Qiang, Y. Yang, Q.D. You, Y.J. Ma, L. Yang, and F.F. Nie et al. Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study Biochem Pharmacol 75 2008 1083 1092
26. J. Yao, R. Hu, J. Sun, B. Lin, L. Zhao, and Y. Sha et al. Oroxylin A prevents inflammation-related tumor through down-regulation of inflammatory gene expression by inhibiting NF-κB signaling Mol Carcinog 53 2014 145 158
27. M. Noda, Y. Omatsu, T. Sugiyama, S. Oishi, N. Fujii, and T. Nagasawa CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice Blood 117 2010 451 458
28. P. Chen, N. Lu, Y. Ling, Y. Chen, H. Hui, and Z. Lu et al. Inhibitory effects of wogonin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-9 Toxicology 282 2011 122 128
29. R.S. Svatek, M. Shulman, P.K. Choudhary, and E. Benaim Critical analysis of prostate-specific antigen doubling time calculation methodology Cancer 106 2006 1047 1053
30. L. Shi, R. Ma, R. Lu, Q. Xu, Z. Zhu, and L. Wang et al. Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU Cancer Lett 269 2008 101 110
31. K. Beider, M. Darash-Yahana, O. Blaier, M. Koren-Michowitz, M. Abraham, and H. Wald et al. Combination of Imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo Mol Cancer Ther 13 2014 1155 1169
32. M. Gatti, A. Pattarozzi, A. Bajetto, R. Wurth, A. Daga, and P. Fiaschi et al. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity Toxicology 314 2013 209 220
33. H.J. Lee, and D.Y. Jo The role of the CXCR4/CXCL12 axis and its clinical implications in gastric cancer Histol Histopathol 27 2012 1155 1161
34. L. Farhana, M.I. Dawson, and J.A. Fontana Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation Cancer Res 65 2005 4909 4917 (Pubitemid 40740831)
35. X.R. Song, Z. Cai, Y. Zheng, G. He, F.Y. Cui, and D.Q. Gong et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles Eur J Pharma Sci 37 2009 300 305
36. A. Peled, and S. Tavor Role of CXCR4 in the pathogenesis of acute myeloid leukemia Theranostics 3 2013 34 39
37. M. Karin Nuclear factor-kappaB in cancer development and progression Nature 441 2006 431 436 (Pubitemid 44050137)
38. M. Karin, and F.R. Greten NF-kappaB: linking inflammation and immunity to cancer development and progression Nat Rev Immunol 5 2005 749 759 (Pubitemid 41400849)
39. C.P. Wong, T.M. Bray, and E. Ho Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages Cancer Lett 276 2009 38 46
40. M.S. Hayden Signaling to NF-κB Genes Dev 18 2004 2195 2224
41. Y. Matsuo, and H.G. Drexler Establishment and characterization of human B cell precursor-leukemia cell lines Leuk Res 22 1998 567 579 (Pubitemid 28327459)
42. Y. Zhou, Y. Xu, Y. Tan, J. Qi, Y. Xiao, and C. Yang et al. Sorcin, an important gene associated with multidrug-resistance in human leukemia cells Leuk Res 30 2006 469 476 (Pubitemid 43254968)
43. Y. Tabe, L. Jin, K. Iwabuchi, R.Y. Wang, N. Ichikawa, and T. Miida et al. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts Leukemia 26 2012 883 892
44. M. Konopleva, Y. Tabe, Z. Zeng, and M. Andreeff Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches Drug Resist Updat 12 2009 103 113
45. F. Arai, A. Hirao, M. Ohmura, H. Sato, S. Matsuoka, and K. Takubo et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche Cell 118 2004 149 161 (Pubitemid 38962572)
46. K. Kojima, T. McQueen, Y. Chen, R. Jacamo, M. Konopleva, and N. Shinojima et al. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 -mediated down-regulation of CXCL12 Blood 118 2011 4431 4439
47. B. Tilton, L. Ho, E. Oberlin, P. Loetscher, F. Baleux, and I. Clark-Lewis et al. Signal transduction by CXC chemokine receptor 4 stromal cell-derived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes J Exp Med 192 2000 313 324 (Pubitemid 30629157)
48. D. Yin, M. Woodruff, Y. Zhang, S. Whaley, J. Miao, and K. Ferslew et al. Morphine promotes Jurkat cell apoptosis through pro-apoptotic FADD/P53 and anti-apoptotic PI3K/Akt/NF-κB pathways J Neuroimmunol 174 2006 101 107
49. J. Molnar, H. Engi, J. Hohmann, P. Molnar, J. Deli, and O. Wesolowska et al. Reversal of multidrug resitance by natural substances from plants Curr Top Med Chem 10 2010 1757 1768
50. X. Song, Y. Chen, Y. Sun, B. Lin, Y. Qin, and H. Hui et al. Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide Pharmacol Rep 64 2012 1189 1199
51. T.L. Tseng, M.F. Chen, M.J. Tsai, Y.H. Hsu, C.P. Chen, and T.J. Lee Oroxylin-A rescues LPS-induced acute lung injury via regulation of NF-kappaB signaling pathway in rodents PLoS ONE 7 2012 e47403
52. T.D. Gilmore Introduction to NF-kappaB: players, pathways, perspectives Oncogene 25 2006 6680 6684 (Pubitemid 44657845)
53. A. Oeckinghaus, and S. Ghosh The NF-kappaB family of transcription factors and its regulation Cold Spring Harb Perspect Biol 1 2009 a000034
54. O.N. Ozes, L.D. Mayo, J.A. Gustin, S.R. Pfeffer, L.M. Pfeffer, and D.B. Donner NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase Nature 401 1999 82 85